^
    1year
    High in vitro and in vivo activity of BI-847325, a dual MEK/Aurora kinase inhibitor, in human solid and hematologic cancer models. (PubMed, Cancer Res Commun)
    BI-847325 showed a broader range of activity than the MEK inhibitor GDC-0623. In conclusion, dual MEK/Aurora kinase inhibition shows remarkable potential for treating multiple types of hematological and solid tumors. The combination with capecitabine was synergistic in colorectal, gastric, and mammary cancer.
    Preclinical • Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF mutation • NRAS mutation
    |
    capecitabine • BI 847325 • GDC-0623